{"id":525199,"date":"2021-08-09T07:18:12","date_gmt":"2021-08-09T11:18:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021\/"},"modified":"2021-08-09T07:18:12","modified_gmt":"2021-08-09T11:18:12","slug":"protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021\/","title":{"rendered":"Protalix BioTherapeutics to Release Second Quarter 2021 Financial Results and Provide a Financial and Business Update on August 16, 2021"},"content":{"rendered":"<div class=\"xn-newslines\">\n<h2 class=\"xn-hedline\">Company to host conference call and webcast at 8:30 a.m. EDT<\/h2>\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>CARMIEL, <span class=\"xn-location\">Israel<\/span>, <span class=\"xn-chron\">Aug. 9, 2021<\/span> \/PRNewswire\/ &#8212; Protalix BioTherapeutics, Inc. (NYSE\u00a0American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx<sup>\u00ae<\/sup> plant cell-based protein expression system, today announced that it will release its financial results for the second quarter 2021 and financial and business update on Monday, August\u00a016, 2021. The Company&#8217;s management will host a conference call to discuss the financial results and provide a business update on recent corporate and clinical developments at 8:30\u00a0a.m. Eastern Daylight Time\u00a0(EDT).<\/p>\n<div id=\"prni_dvprnejpgb3ddleft\" dir=\"ltr\">\n        <img decoding=\"async\" id=\"prnejpgb3ddleft\" title=\"Protalix Biotherapeutics Logo\" border=\"0\" alt=\"Protalix Biotherapeutics Logo\" align=\"middle\" src=\"https:\/\/mma.prnewswire.com\/media\/999479\/Protalix_Biotherapeutics_Logo.jpg\" \/>\n      <\/div>\n<p>\n        <b>Conference Call Details:<\/b>\n      <\/p>\n<p id=\"indentid\" class=\"prnml40\">\n        <span class=\"xn-chron\">Monday, August 16, 2021<\/span>, 8:30\u00a0a.m. Eastern Daylight Time (EDT)<br \/>Domestic:\u00a0\u00a0877-423-9813<br \/>International: \u00a0201-689-8573<br \/>Conference ID: \u00a013721687<\/p>\n<p>The conference call will be webcast live from the Company&#8217;s website and will be available via the following links:<\/p>\n<p>\n        <b>Webcast Details:<\/b>\n      <\/p>\n<p id=\"indentid\" class=\"prnml40\">Company Link: <a target=\"_blank\" href=\"https:\/\/protalixbiotherapeutics.gcs-web.com\/events0\" rel=\"nofollow noopener\">https:\/\/protalixbiotherapeutics.gcs-web.com\/events0<\/a><br \/>Webcast Link: <a target=\"_blank\" href=\"https:\/\/tinyurl.com\/3y2rx6za\" rel=\"nofollow noopener\">https:\/\/tinyurl.com\/3y2rx6za<\/a><br \/>Conference ID: \u00a013721687<\/p>\n<p>Please access the websites at least 15 minutes ahead of the conference to register, download and install any necessary audio software.<\/p>\n<p>The conference call will be available for replay for two weeks on the Events Calendar of the Investors section of the Company&#8217;s website, at the above link.<\/p>\n<p>\n        <b>About Protalix BioTherapeutics, Inc.<\/b>\n      <\/p>\n<p>Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based protein expression system, ProCellEx<sup>\u00ae<\/sup>. Protalix was the first company to gain U.S.\u00a0Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix&#8217;s unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. <\/p>\n<p>Protalix&#8217;s first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the FDA in <span class=\"xn-chron\">May 2012<\/span> and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding <span class=\"xn-location\">Brazil<\/span>, where Protalix retains full rights. <\/p>\n<p>Protalix&#8217;s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human \u03b1\u2013Galactosidase\u2013A protein for the proposed treatment of Fabry disease; OPRX\u2013106, an orally-delivered anti-inflammatory treatment; alidornase alfa for the treatment of Cystic Fibrosis; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in <span class=\"xn-location\">the United States<\/span> and outside <span class=\"xn-location\">the United States<\/span>, for the development and commercialization of pegunigalsidase alfa. <\/p>\n<p>\n        <b>Investor Contact<\/b>\n      <\/p>\n<p>\n        <span class=\"xn-person\">Chuck Padala<\/span>, Managing Director<br \/>LifeSci Advisors<br \/>646-627-8390 <br \/><a target=\"_blank\" href=\"mailto:chuck@lifesciadvisors.com\" rel=\"nofollow noopener\">chuck@lifesciadvisors.com<\/a><\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO68698&amp;sd=2021-08-09\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021-301350992.html\">https:\/\/www.prnewswire.com\/news-releases\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021-301350992.html<\/a><\/p>\n<p>SOURCE  Protalix BioTherapeutics, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=IO68698&amp;Transmission_Id=202108090715PR_NEWS_USPR_____IO68698&amp;DateId=20210809\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Company to host conference call and webcast at 8:30 a.m. EDT PR Newswire CARMIEL, Israel, Aug. 9, 2021 \/PRNewswire\/ &#8212; Protalix BioTherapeutics, Inc. (NYSE\u00a0American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx\u00ae plant cell-based protein expression system, today announced that it will release its financial results for the second quarter 2021 and financial and business update on Monday, August\u00a016, 2021. The Company&#8217;s management will host a conference call to discuss the financial results and provide a business update on recent corporate and clinical developments at 8:30\u00a0a.m. Eastern Daylight Time\u00a0(EDT). Conference Call Details: Monday, August 16, 2021, 8:30\u00a0a.m. Eastern Daylight Time (EDT)Domestic:\u00a0\u00a0877-423-9813International: \u00a0201-689-8573Conference ID: \u00a013721687 The conference &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Protalix BioTherapeutics to Release Second Quarter 2021 Financial Results and Provide a Financial and Business Update on August 16, 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-525199","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Protalix BioTherapeutics to Release Second Quarter 2021 Financial Results and Provide a Financial and Business Update on August 16, 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Protalix BioTherapeutics to Release Second Quarter 2021 Financial Results and Provide a Financial and Business Update on August 16, 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company to host conference call and webcast at 8:30 a.m. EDT PR Newswire CARMIEL, Israel, Aug. 9, 2021 \/PRNewswire\/ &#8212; Protalix BioTherapeutics, Inc. (NYSE\u00a0American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx\u00ae plant cell-based protein expression system, today announced that it will release its financial results for the second quarter 2021 and financial and business update on Monday, August\u00a016, 2021. The Company&#8217;s management will host a conference call to discuss the financial results and provide a business update on recent corporate and clinical developments at 8:30\u00a0a.m. Eastern Daylight Time\u00a0(EDT). Conference Call Details: Monday, August 16, 2021, 8:30\u00a0a.m. Eastern Daylight Time (EDT)Domestic:\u00a0\u00a0877-423-9813International: \u00a0201-689-8573Conference ID: \u00a013721687 The conference &hellip; Continue reading &quot;Protalix BioTherapeutics to Release Second Quarter 2021 Financial Results and Provide a Financial and Business Update on August 16, 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-09T11:18:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/999479\/Protalix_Biotherapeutics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Protalix BioTherapeutics to Release Second Quarter 2021 Financial Results and Provide a Financial and Business Update on August 16, 2021\",\"datePublished\":\"2021-08-09T11:18:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021\\\/\"},\"wordCount\":453,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/999479\\\/Protalix_Biotherapeutics_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021\\\/\",\"name\":\"Protalix BioTherapeutics to Release Second Quarter 2021 Financial Results and Provide a Financial and Business Update on August 16, 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/999479\\\/Protalix_Biotherapeutics_Logo.jpg\",\"datePublished\":\"2021-08-09T11:18:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/999479\\\/Protalix_Biotherapeutics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/999479\\\/Protalix_Biotherapeutics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Protalix BioTherapeutics to Release Second Quarter 2021 Financial Results and Provide a Financial and Business Update on August 16, 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Protalix BioTherapeutics to Release Second Quarter 2021 Financial Results and Provide a Financial and Business Update on August 16, 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021\/","og_locale":"en_US","og_type":"article","og_title":"Protalix BioTherapeutics to Release Second Quarter 2021 Financial Results and Provide a Financial and Business Update on August 16, 2021 - Market Newsdesk","og_description":"Company to host conference call and webcast at 8:30 a.m. EDT PR Newswire CARMIEL, Israel, Aug. 9, 2021 \/PRNewswire\/ &#8212; Protalix BioTherapeutics, Inc. (NYSE\u00a0American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx\u00ae plant cell-based protein expression system, today announced that it will release its financial results for the second quarter 2021 and financial and business update on Monday, August\u00a016, 2021. The Company&#8217;s management will host a conference call to discuss the financial results and provide a business update on recent corporate and clinical developments at 8:30\u00a0a.m. Eastern Daylight Time\u00a0(EDT). Conference Call Details: Monday, August 16, 2021, 8:30\u00a0a.m. Eastern Daylight Time (EDT)Domestic:\u00a0\u00a0877-423-9813International: \u00a0201-689-8573Conference ID: \u00a013721687 The conference &hellip; Continue reading \"Protalix BioTherapeutics to Release Second Quarter 2021 Financial Results and Provide a Financial and Business Update on August 16, 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-09T11:18:12+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/999479\/Protalix_Biotherapeutics_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Protalix BioTherapeutics to Release Second Quarter 2021 Financial Results and Provide a Financial and Business Update on August 16, 2021","datePublished":"2021-08-09T11:18:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021\/"},"wordCount":453,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/999479\/Protalix_Biotherapeutics_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021\/","name":"Protalix BioTherapeutics to Release Second Quarter 2021 Financial Results and Provide a Financial and Business Update on August 16, 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/999479\/Protalix_Biotherapeutics_Logo.jpg","datePublished":"2021-08-09T11:18:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/999479\/Protalix_Biotherapeutics_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/999479\/Protalix_Biotherapeutics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-release-second-quarter-2021-financial-results-and-provide-a-financial-and-business-update-on-august-16-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Protalix BioTherapeutics to Release Second Quarter 2021 Financial Results and Provide a Financial and Business Update on August 16, 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/525199","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=525199"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/525199\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=525199"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=525199"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=525199"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}